CATALYST PHARMACEUTICALS, INC. CPRX
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
4/9
Piotroski F — financial health
14.1
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $589.0M | $214.3M | — | $208.6M | $954.3M |
| 2024 | $491.7M | $163.9M | — | $239.3M | $727.6M |
| 2023 | $398.2M | $71.4M | — | $143.4M | $387.9M |
| 2022 | $214.2M | $83.1M | — | $116.0M | $300.4M |
| 2021 | $140.8M | $39.5M | — | $59.4M | $206.8M |
| 2020 | $119.1M | $75.0M | — | $45.0M | $169.6M |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 14.1 (safe)
- Working capital / assets 0.677
- Retained earnings / assets 0.43
- EBIT / assets 0.233
- Equity / liabilities 6.374
Source: SEC EDGAR filings · CIK 0001369568 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.